| Catalog No. |
TD-HS856106 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Host species |
Humanized |
| Isotype |
IgG4-kappa-[scFv]2 |
| Expression system |
Mammalian Cells |
| Species |
Human |
| Clonality |
Monoclonal |
| Target |
CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
| Endotoxin level |
Please contact with the lab for this information. |
| Purity |
>95% as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
Q16552 & Q9Y275 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS, pH 7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| Alternate Names |
Bispecific, LY 3090106, LY-3090106, LY3090106, CAS: 1849636-24-3 |
| Background |
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research. |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |